Seven Eight Capital LP boosted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 282.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,400 shares of the medical instruments supplier’s stock after buying an additional 9,900 shares during the quarter. Seven Eight Capital LP’s holdings in West Pharmaceutical Services were worth $1,267,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Riverhead Capital Management LLC boosted its stake in West Pharmaceutical Services by 66.5% during the second quarter. Riverhead Capital Management LLC now owns 2,830 shares of the medical instruments supplier’s stock valued at $268,000 after buying an additional 1,130 shares in the last quarter. Capital Fund Management S.A. boosted its stake in West Pharmaceutical Services by 2.9% during the second quarter. Capital Fund Management S.A. now owns 100,000 shares of the medical instruments supplier’s stock valued at $9,452,000 after buying an additional 2,783 shares in the last quarter. Financial Counselors Inc. boosted its stake in West Pharmaceutical Services by 4.0% during the second quarter. Financial Counselors Inc. now owns 14,994 shares of the medical instruments supplier’s stock valued at $1,417,000 after buying an additional 577 shares in the last quarter. Wells Fargo & Company MN boosted its stake in West Pharmaceutical Services by 6.2% during the second quarter. Wells Fargo & Company MN now owns 593,952 shares of the medical instruments supplier’s stock valued at $56,141,000 after buying an additional 34,723 shares in the last quarter. Finally, Eaton Vance Management boosted its stake in West Pharmaceutical Services by 6.0% during the second quarter. Eaton Vance Management now owns 308,728 shares of the medical instruments supplier’s stock valued at $29,181,000 after buying an additional 17,512 shares in the last quarter. 91.25% of the stock is owned by institutional investors and hedge funds.

WARNING: “Seven Eight Capital LP Increases Position in West Pharmaceutical Services, Inc. (WST)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/15/seven-eight-capital-lp-increases-position-in-west-pharmaceutical-services-inc-wst.html.

Several research analysts recently weighed in on the company. Jefferies Group LLC raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $115.00 target price for the company in a research note on Friday. BidaskClub cut West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 target price for the company in a research note on Friday, June 9th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. West Pharmaceutical Services presently has an average rating of “Hold” and a consensus target price of $98.52.

West Pharmaceutical Services, Inc. (NYSE WST) opened at 91.72 on Friday. West Pharmaceutical Services, Inc. has a 52 week low of $70.17 and a 52 week high of $99.91. The company has a market cap of $6.79 billion, a PE ratio of 39.36 and a beta of 1.13. The company’s 50-day moving average price is $87.31 and its 200 day moving average price is $89.20.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The company had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406.00 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 earnings per share. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post $2.68 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be given a dividend of $0.14 per share. The ex-dividend date of this dividend is Tuesday, October 17th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.61%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. West Pharmaceutical Services’s payout ratio is presently 22.22%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.